NAD(P)H氧化酶P22phox亚基C242T多态性与蒽环类药物治疗弥漫大B细胞淋巴瘤化疗疗效的相关性研究

目的探讨NAD(P)H氧化酶P22phox亚基C242T基因多态性与以蒽环类药物为基础的化疗方案治疗弥漫大B细胞淋巴瘤化疗疗效的关系。方法收集经病理形态学和免疫组织化学确诊DLBCL患者32例,采用PCR-RFLP技术检测C242T位点的基因型,观察其不同基因型与化疗效果的关系。结果 32例DLBCL患者中,CC基因型22例(68.8%),CT基因型10例(31.2%),其中16例完全缓解,9例部分缓解,近期缓解率为78.1%。其中CC型有效20例(62.5%),CT型有效5例(15.6%),差异有统计学意义(P=0.019)。结论野生基因型(CC)对以蒽环类为基础化疗敏感,临床疗效优于突变型。

Association between the Polymorphism of NAD(P)H Oxidase Subunit p22phox C242T gene and response Chemotherapy of DLBCL patients treated with anthracycline-Based Chemotherapy

Objective To investigate association between the polymorphism of NAD(P)H Oxidase Subunit p22phox C242T gene and response chemotherapy of DLBCL patients treated with anthracycline-Based chemotherapy.Methods Thirty-two patients were enrolled into our study which were confirmed by pathologic and immunohistochemical diagnosis.The single nucleotide polymorphism of C242T were detected using PCR-restriction fragment length po1ymorphism method.The relationship between SNP of the C242T gene and clinical effect was analyzed.Results The frequencies of C242T genetype CC were 68.8%,CT were 31.2%.Total response rate of chemotherapy was 78.1%,including 16 patients with complete response,9 with partial response.The response rate in patients with CC genotype(62.5%) was significantly higher than patients with CT genotype(15.6%),P=0.019.Conclusion Compared with mutation genotype,wild genotype(cc) in patients has higher response rate and its clinical effect is better than the mutation type.